James Woo
5 Papers
James Woo is an academic researcher. The author has contributed to research in topics: Biology & In silico. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
Candida albicans Stimulates IL-23 Release by Human Dendritic Cells and Downstream IL-17 Secretion by Vδ1 T Cells
Christina O. Maher,Katie Dunne,Ross Comerford,Siobhan O’Dea,Aisling Loy,James Woo,Thomas R. Rogers,Fiona Mulcahy,Pádraic J. Dunne,Derek G. Doherty +9 more
TL;DR: It is shown that circulating Vδ1 T cell numbers are particularly high in patients with HIV and candidiasis, and that these cells expand and produce IL-17 in response to Candida albicans in vitro, by a mechanism that involves IL-23 release by DCs.
POS0119 XmAb564, A NOVEL POTENCY-REDUCED IL-2 FC FUSION PROTEIN SELECTIVELY EXPANDS REGULATORY T CELLS: RESULTS FROM A SINGLE ASCENDING DOSE STUDY IN HEALTHY ADULT VOLUNTEERS
TL;DR: XmAb564 as discussed by the authors is a potency reduced, monomeric human IL-2 heterodimeric Fc-fusion protein with extended half-life and increased binding affinity for IL 2 receptor alpha to selectively expand Tregs, being developed for the treatment of autoimmune diseases.
Abstract 3152: Targetable public neoantigens are generated by tumor-wide cancer-specific splicing events in gliomas
Darwin Kwok,Takahide Nejo,Nicholas O. Stevers,Lee Chen,Kaori Okada,Chibo Hong,G Chan,Akane Yamamichi,Aidan Du,Maggie Colton,James Woo,Joseph F. Costello,Hideho Okada +12 more
TL;DR: Kwok et al. as mentioned in this paper developed a comprehensive in silico pipeline for detecting tumor-specific alternative splicing events (neojunctions), and successfully identified tumor-wide, public, alternatively spliced neoantigens (ASNs) that elicited CD8+ T-cell-mediated immune responses.
80 Tumor-specific alternative splicing generates immunogenic spatially-conserved HLA-binding neoantigens detected through integrative transcriptomic and proteomic analyses
Darwin Kwok,Takahide Nejo,Chibo Hong,Aidan Du,Maggie Colton,James Woo,Joseph M. Costello,Hideho Okada +7 more
- 01 Nov 2022
TL;DR: In this paper , the authors investigated alternative-splicing (AS) events within glioma to identify novel MHC-I-presented neoantigens through an integrative transcriptomic and proteomic computational pipeline, complemented by an extensive spatiotemporal analysis of the AS candidates.
Abstract 4170: Integrative transcriptomic and proteomic analysis reveals immunogenic and spatially-conserved HLA-binding neoantigen targets derived from tumor-specific alternative splicing events
TL;DR: Tumor-specific neojunctions identified in this unique integrative pipeline present novel candidate immunotherapy targets for gliomas and offer a new avenue in neoantigen discovery across cancer types.